Skip to main content

Advertisement

ADVERTISEMENT

Videos

Brian M. Slomovitz, MD
Conference Coverage
03/18/2024

Featuring Brian M. Slomovitz, MD

Featuring Brian M. Slomovitz, MD ...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting,...
03/18/2024
Oncology
BDHC thumbnail
Breaking Down Health Care
03/18/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In this first installment of the Breaking Down Health Care video series, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the fundamentals of how health care works in the United States, including covering the main payers, to set the...
In this first installment of the Breaking Down Health Care video series, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the fundamentals of how health care works in the United States, including covering the main payers, to set the...
In this first installment of the...
03/18/2024
Cancer Care Business Exchange

Advertisement

David Cibula, MD, PhD
Conference Coverage
03/17/2024

Featuring David Cibula, MD, PhD

Featuring David Cibula, MD, PhD ...
At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...
At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...
At the SGO 2024 Annual Meeting,...
03/17/2024
Oncology
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
03/12/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses...
03/12/2024
Oncology
Video thumbnail screenshot.
Videos
03/11/2024

Featuring Barbara McAneny, MD, and Sibel Blau, MD

Featuring Barbara McAneny, MD, and Si...
Longtime industry leaders Barbara McAneny, MD, and Sibel Blau, MD, have joined forces to create ONCare Alliance, a strategic collaboration that aims to redefine the independent practice in community cancer care.
Longtime industry leaders Barbara McAneny, MD, and Sibel Blau, MD, have joined forces to create ONCare Alliance, a strategic collaboration that aims to redefine the independent practice in community cancer care.
Longtime industry leaders...
03/11/2024
Cancer Care Business Exchange

Advertisement

Jennifer Amengual, MD, Columbia University
Conference Coverage
03/11/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
03/11/2024
Lymphoma, Leukemia & Myeloma Network
Kerry Rogers, MD.
Videos
03/07/2024

Featuring Kerry Rogers, MD

Featuring Kerry Rogers, MD
In this interview, Kerry Rogers, MD, from The Ohio State University, provides insight into the newly available treatments for chronic lymphocytic leukemia (CLL) and how care for patients with CLL has changed over time.
In this interview, Kerry Rogers, MD, from The Ohio State University, provides insight into the newly available treatments for chronic lymphocytic leukemia (CLL) and how care for patients with CLL has changed over time.
In this interview, Kerry Rogers,...
03/07/2024
Journal of Clinical Pathways
Amanda Nizam, MD
Videos
03/04/2024

Featuring Amanda Nizam, MD

Featuring Amanda Nizam, MD
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the...
03/04/2024
Journal of Clinical Pathways

Advertisement

Stephen Speicher, MD
Videos
03/01/2024

Featuring Stephen V. Speicher, MD, MS

Featuring Stephen V. Speicher, MD, MS...
Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”
Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”
Stephen V. Speicher, MD, MS,...
03/01/2024
Journal of Clinical Pathways
Nicole Lamanna, MD
Conference Coverage
02/29/2024

Featuring Nicole Lamanna, MD

Featuring Nicole Lamanna, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia &...
02/29/2024
Lymphoma, Leukemia & Myeloma Network

Advertisement